C-021

• Description:

  C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor with an IC50 of 18 nM[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319

• Target:

  CCR

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein; Immunology/Inflammation

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/c-021.html

• Purity:

  99.95

• Solubility:

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 80°C) |Ethanol : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  COC1=CC2=NC (N3CCC (N4CCCCC4) CC3) =NC (NC5CCCCCC5) =C2C=C1OC

• Molecular Formula:

  C27H41N5O2

• Molecular Weight:

  467.65

• Precautions:

  H302, H315, H319

• References & Citations:

  [1]Yokoyama K, et al. Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines. Bioorg Med Chem. 2009 Jan 1;17 (1) :64-73.|[2]Matthew McMillin, et al. Neuronal CCL2 is upregulated during hepatic encephalopathy and contributes to microglia activation and neurological decline. J Neuroinflammation. 2014 Jul 10;11:121.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CCR4

• CAS Number:

  864289-85-0